IMVT250117C45000
- 0.55
- 0.000.00%
Immunovant Newsroom
Wolfe Research Downgrades Immunovant(IMVT.US) to Hold Rating
Wolfe Research Downgrades Immunovant to Peer Perform From Outperform
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth
Wells Fargo Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $45
Immunovant Price Target Lowered to $45 From $47 at Wells Fargo
Immunovant Is Maintained at Overweight by Wells Fargo
Immunovant Analyst Ratings
FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline With Promising Results and FDA Green Light for Pivotal Trial
Graves' Disease Pipeline Drug Research Report 2024 Featuring Viridian Therapeutics, Immunovant Sciences, Apitope International, Sling Therapeutics, and Novartis
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Have Immunovant Insiders Been Selling Stock?
Insider Sale: Chief Legal Officer of $IMVT (IMVT) Sells 3,650 Shares
Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024?
Wells Fargo Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $47
Immunovant's IMVT-1402: A Promising Breakthrough for Graves' Disease With Significant Market Potential
Argenx Upgraded at Wolfe on Myasthenia Gravis Dominance
Immunovant's Strategic Advances in Autoimmune Therapies
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $48 to $58